PGR and triple-negative breast carcinoma: For triple negative breast cancer, which is characterized by the absence of expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), it is currently the only available systemic treatment option.